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The link between homocysteine and the vascular pathology of arteriosclerosis was first described almost 30 years ago.' However, it is only recently that hyperhomocysteinaemia has achieved widespread recognition as an independent risk factor for vascular disease, including coronary heart disease, stroke and peripheral vascular disease.' This renewed interest has stimulated laboratories to re-examine methods for the estimation of homocysteine in plasma.
The major problem that bedevils epidemiological and clinical studies of homocysteine is the increase in plasma homocysteine concentration that occurs if blood is not centrifuged immediately after collection. Plasma total homocysteine concentration rises by up to 10% per hour in blood kept at room temperature, largely as a result of the conversion of S-adenosylmethionine and S-adenosylhomocysteine to homocysteine within erythrocytes.' Since this laboratory receives blood samples for epidemiological studies by post, our aim was to identify an additive to blood which would stabilize homocysteine levels for up to 72 h, thereby avoiding the need to centrifuge samples immediately after collection.
Inhibitors of the following key steps in homocysteine metabolism were examined (Fig. I): the conversion of homocysteine to methionine (inhibited by S-adenosylhomocysteine); methionine to S-adenosylmethionine (an adenosine triphosphate-dependent step inhibited by sodium fluoride); S-adenosylhomocysteine to homocysteine (inhibited by 3-deazaadenosine, an adenosine analogue); and homocysteine to cystathionine, a vitamin-B6-dependent step (inhibited by deoxypyridoxine 5-phosphate). Homocysteine erythrocyte efflux was inhibited by 2-amino-2-norbornanecarboxylic acid (BCH).
Correspondence: Dr D Stansbie.
780

MATERIALS AND METHODS
Blood was collected into ethylenediaminetetraacetic acid (EDTA) and sodium fluoride/potassium oxalate vacutainers (Becton Dickinson, Meylan, France) on two occasions from healthy male and female laboratory workers (22-56 years) between 09·00 and 10·00 h after a light breakfast. Aliquots of whole blood from the EDTA tubes were immediately transferred to plastic tubes containing inhibitors (Sigma Chemical Co., Poole, UK) at a final concentration of 100,umol/L (except sodium fluoride, 60 mrnol/L). Blood was incubated at ambient temperature, re-sampled at intervals, centrifuged and plasma stored at -20"C. Plasma total homocysteine was assayed following reduction by sodium borohydride and derivatization with bromobimane by gradient elution on a reversed phase high-performance liquid chromatography system with fluorometric detection." The betweenbatch percentage coefficient of variation (%CY) at a homocysteine concentration of 20·2/lmol/L was 5·6 (n = 22).
RESULTS
In preliminary studies over a 6-h incubation period, S-adenosylhomocysteine, BCH and deoxypyridoxine 5-phosphate not only failed to prevent increases, but resulted in greater elevations of plasma homocysteine than did EDTA alone; in addition, BCH resulted in gross haemolysis. Therefore, these inhibitors were not considered further. In contrast, 3-deazaadenosine and sodium fluoride showed initial promise and their effectiveness as a preservative of plasma homocysteine was examined in two separate experiments (see Table I ). Incubation of blood at room temperature with 3-deazaadenosine virtually eliminated the three-fold increase in homocysteine seen at 72 h with EDTA alone. Plasma homocysteine concentrations were completely stable for up to 24 h in the presence of 3-deazaadenosine and only increased by about 10% at 72 h. Blood collected into fluoride showed a trend to higher initial homocysteine concentrations and prolonged incubation resulted in gross hacmolysis, which may account for the decline in mean homocysteine concentration to 79'Yo of initial values at 72 h. In a further experiment plasma homocysteine was measured in EDTA blood received for hacmatological analysis (normal indices; II = 49) immediately and 72 h after incubation at room temperature with or without 3-deazaadenosine. Mean (SD) plasma homocysteine concentrations were 11·6 (3'5),12,5 (4'1) and 25·2 (6'4) j.lmol/L, respectively. The addition of 100 j.lmol/L 3-deazaadenosine to whole blood therefore red uced increases in plasma homocysteine to less than 8% even after 72 h storage at ambient temperature. Varying the concentration of 3-deazaadenosine between 50 j.lmol/L and 1·00 mrnol/L resulted in no change in its efficacy. Al-Khafaji et al.
CONCLUSIONS
The use of 3-deazaadenosine, which inhibits the final step in the synthesis of homocysteine, is a convenient way to minimize artefactual increases in plasma homocysteine in blood samples which cannot be separated immediately. Fluoride is also effective to an extent but we and others have found discrepancies between plasma homocysteine levels in blood collected into fluoride compared with blood collected into EDTA. 5 ,6 In our study homocysteine concentrations were immediately 13% higher in samples collected into fluoride; similar effects have been observed before and attributed to osmotic shifts in red cell water.? In addition, fluoride only preserves basal homocysteine levels for a few hours-" and subsequent gross haemolysis is associated with a significant decline in concentration. We conclude that the addition of 100/lmol/L 3-deazaadenosine to blood is an effective preservative which prevents changes in plasma homocysteine for at least 24 h and reduces increases to less than 10% at 72 h, thereby enabling the laboratory to measure this newly Ann cu« Biochem 1998: 3S recognized vascular risk factor In samples received by first class post.
